Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases

Journal of Clinical Oncology

Volumn 34, Issue 9, 2016, Pages 945-952

  Freedman, Rachel A ^a   Gelman, Rebecca S ^a   Wefel, Jeffrey S ^d   Melisko, Michelle E ^f   Hess, Kenneth R ^d   Connolly, Roisin M ^g   Van Poznak, Catherine H ^h   Niravath, Polly A ^e   Puhalla, Shannon L ⁱ   Ibrahim, Nuhad ^d   Blackwell, Kimberly L ^j   Moy, Beverly ^b   Herold, Christina ^a   Liu, Minetta C ^k   Lowe, Alarice ^c   Agar, Nathalie Y R ^c   Ryabin, Nicole ^a   Farooq, Sarah ^a   Lawler, Elizabeth ^a   Rimawi, Mothaffar F ^e   Krop, Ian E ^a   Wolff, Antonio C ^g   Winer, Eric P ^a   Lin, Nancy U ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NERATINIB; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COGNITION; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; LIVER FUNCTION TEST; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIAL; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-2;

EID: 84962094467     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.0343     Document Type: Article

References (46)

1. Lin NU, Winer EP: Brain metastases: The HER2 paradigm. Clin Cancer Res 13: 1648-1655, 2007
2. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972-2977, 2003
3. Pestalozzi BC: Brain metastases and subtypes of breast cancer. Ann Oncol 20: 803-805, 2009
4. Kennecke H, Yerushalmi R, Woods R, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28: 3271-3277, 2010
5. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 22: 3608-3617, 2004
6. Pestalozzi BC, Holmes E, de Azambuja E, et al: CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14: 244-248, 2013
7. Olson EM, Najita JS, Sohl J, et al: Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22: 525-531, 2013
8. Mahmoud-Ahmed AS, Suh JH, Lee SY, et al: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys 54: 810-817, 2002
9. Eichler AF, Kuter I, Ryan P, et al: Survival in patients with brain metastases from breast cancer: The importance of HER-2 status. Cancer 112: 2359-2367, 2008
10. Gori S, Rimondini S, De Angelis V, et al: Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: Incidence, survival, and risk factors. Oncologist 12: 766-773, 2007
11. Karam I, Hamilton S, Nichol A, et al: Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the pre-trastuzumab and trastuzumab eras. Radiat Oncol 8: 12, 2013
12. Melisko ME, Moore DH, Sneed PK, et al: Brain metastases in breast cancer: Clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 88: 359-365, 2008
13. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30: 419-425, 2012
14. Rabindran SK, Discafani CM, Rosfjord EC, et al: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958-3965, 2004
15. Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15: 2552-2558, 2009
16. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28: 1301-1307, 2010
17. Martin M, Bonneterre J, Geyer CE Jr, et al: A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 49: 3763-3772, 2013
18. Puma Biotechnology: Neratinib investigator brochure Los Angeles, CA, Puma Biotechnology, 2012
19. Kuhn JG, Robbins H, Mehta M, et al: Tumor sequestration of lapatinib (NABTC 04-01). Neurooncol 10: 783, 2008 (abstr ET-05)
20. Bachelot T, Romieu G, Campone M, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 14: 64-71, 2013
21. Lin NU, Diéras V, Paul D, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15: 1452-1459, 2009
22. Wolff AC, Hammond EH, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline update. J Clin Oncol 31: 3997-4013, 2013
23. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009
24. Schwartz LH, Bogaerts J, Ford R, et al: Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 45: 261-267, 2009
25. Riethdorf S, Fritsche H, Müller V, et al: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res 13: 920-928, 2007
26. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004
27. Sprangers MA, Cull A, Bjordal K, et al.; EORTC Study Group on Quality of Life: The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: Guidelines for developing questionnaire modules. Qual Life Res 2: 287-295, 1993
28. King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5: 555-567, 1996
29. Cocks K, King MT, Velikova G, et al: Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 data in randomised controlled trials. Eur J Cancer 44: 1793-1798, 2008
30. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
31. Lin NU, Lee EQ, Aoyama H, et al: Response assessment criteria for brain metastates: Proposal from the RANO group. Lancet Oncol 16: e270-e278, 2015
32. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004
33. Ruff RM, Light RH, Parker SB, et al: Benton Controlled Oral Word Association Test: Reliability and updated norms. Arch Clin Neuropsychol 11: 329-338, 1996
34. Tombaugh TN: Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol 19: 203-214, 2004
35. Benedict RHB, Schretlen D, Groninger L, et al: Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12: 43-55, 1998
36. Wefel JS, Cloughesy T, Zazzali JL, et al: Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-oncol 13: 660-668, 2011
37. Lin NU, Carey LA, Liu MC, et al: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993-1999, 2008
38. Polli JW, Humphreys JE, Harmon KA, et al: The role of efflux and uptake transporters in [N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)-ethyl]aminomethyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36: 695-701, 2008
39. Morikawa A, Peereboom DM, Thorsheim HR, et al: Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: A prospective study. Neuro-oncol 17: 289-295, 2015
40. Lin NU, Eierman W, Greil R, et al: Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105: 613-620, 2011
41. Saura C, Martin M, Moroose R, et al: Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: A phase 1/2 study. Presented at the San Antonio Breast Cancer Symposium San Antonio, TX December 10-13, 2009 doi: 10.1158/0008-5472.SABCS-09-5108
42. Pierga JY, Bidard FC, Cropet C, et al: Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: The LANDSCAPE trial. Ann Oncol 24: 2999-3004, 2013
43. Smerage JB, Barlow WE, Hortobagyi GN, et al: Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32: 3483-3489, 2014
44. Chang EL, Wefel JS, Hess KR, et al: Neuro-cognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10: 1037-1044, 2009
45. Brown PD, Pugh S, Laack NN, et al.; Radiation Therapy Oncology Group (RTOG): Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neurooncol 15: 1429-1437, 2013
46. Meyers CA, Smith JA, Bezjak A, et al: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22: 157-165, 2004